Erich Reinhardt, member of the Managing Board of Siemens AG and president and CEO of Siemens Medical Solutions, has been awarded the International Neurobionics Award 2006 in the amount of 25,000 Euro by the International Neurobionics Foundation. Erich R. Reinhardt would like to promote young scientists with his prize money. The modern science of neurobionics connects neurosciences, biology and applied medical engineering to develop new medical procedures that reestablish destroyed nerve paths or nerve contacts after illnesses or accidents. The International Neurobionics Foundation provides financial and conceptual support to projects that help people who are blind, deaf or paralyzed to fully or partially regain their lost sense or mobility through the use of modern microchip implantation. The foundation promotes groundbreaking work in the interdisciplinary field of neurobionics. Since 1998, it also awards outstanding pioneers and personalities of the various neurobionic disciplines with the International Neurobionics Award in the area of biomedical research and technology that serve for rehabilitation, implementation or restoration of neurological functions.
Erich R. Reinhardt has been honored with the international award for his efforts in the area of imaging methods. According to Madjid Samii, President of the Senate of the International Neurobionics Foundation, without these activities the extraordinary recent successes in neurosurgery would not have been possible. Reinhardt accepted the award in the name of the Med Group's work: "I am very happy about this award. It shows me that we are not only facilitating high-quality, patient-oriented medical care but also fostering research for future generations."
Siemens Medical Solutions of Siemens AG (NYSE: SI) is one of the world's largest suppliers to the healthcare industry. The company is known for bringing together innovative medical technologies, healthcare information systems, management consulting, and support services, to help customers achieve tangible, sustainable, clinical and financial outcomes. Recent acquisitions in the area of in-vitro diagnostics such as Diagnostic Products Corporation and Bayer Diagnostics mark a significant milestone for Siemens as it becomes the first full service diagnostics company. Employing more than 41,000 people worldwide and operating in over 130 countries, Siemens Medical Solutions reported sales of 8.23 billion EUR, orders of 9.33 billion EUR and group profit of 1.06 billion EUR for fiscal 2006 (Sept. 30). Further information can be found by visiting www.siemens.com/medical